Kaneka stock falls 1.32 percent as health investment expands

Published on 10/08/2026 at 08:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Kaneka stock was trading at JPY 5,982 on October 8, 2026, with a 52-week high of JPY 6,570. Q1 revenue reached JPY 223.025 billion for the period ended June 30, 2026.

Kaneka, JP3215800008, Illustration mit AI erstellt.

Kaneka stock (ISIN JP3215800008) was trading at JPY 5,982 on the Tokyo Stock Exchange on October 8, 2026, down 1.32 percent from the prior close. NutraIngredients reported on October 8, 2026, that Kaneka plans to continue investing in ubiquinol research, education programs and new formulations.

Ubiquinol expands health strategy

The report followed Kaneka ubiquinol winning the Ingredient of the Year: Healthspan award at a ceremony in Bangkok on September 2, 2026. Kaneka said its research on ubiquinol, the active form of coenzyme Q10, has continued for more than 50 years, giving the product a long development history.

For investors, the health initiative adds a consumer-facing growth angle to a company whose portfolio also spans chemicals, materials, health care and nutrition. The award does not quantify future sales, so the key financial test remains whether the health business can contribute alongside Kaneka's established industrial operations.

Quarterly revenue reaches JPY 223.025 billion

Investing.com reported that Kaneka's fiscal Q1 ended June 30, 2026, with revenue of JPY 223.025 billion and net income of JPY 8.941 billion. Revenue was 4.5 percent higher than the JPY 213.360 billion recorded in the preceding quarter, while net income was 28.7 percent lower than JPY 12.537 billion.

The quarterly mix matters because the revenue increase did not translate into sequential earnings growth. Kaneka's operating profit reached JPY 14.944 billion in fiscal Q1, compared with JPY 9.440 billion in the preceding quarter, indicating that the reported net income decline also reflected changes below operating profit.

Neutral consensus stays below the quote

On September 29, 2026, Minkabu reported a Neutral consensus from six analysts, with an average 12-month target of JPY 5,541.67. The target lies 7.4 percent below the October 8 trading price of JPY 5,982.

That valuation checkpoint contrasts with the stock's recent market position. The October 8 price remained JPY 588 below the 52-week high of JPY 6,570 and JPY 1,900 above the 52-week low of JPY 4,082, placing the shares closer to the upper end of the annual range.

Kaneka stock trades near yearly high

Kaneka stock was last at JPY 5,982 on the Tokyo Stock Exchange on October 8, 2026, with volume of 108,600 shares and a market capitalization of JPY 360.3 billion. The combination of a health investment story, sequential revenue growth and a Neutral analyst consensus leaves earnings conversion as the central measure for the next update.